{"data":[{"accessionNo":"0001907884-26-000015","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":"92337R101","securityClass":"Class A common stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Kynam Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":4.01,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0001907884-26-000015","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":"92337R101","securityClass":"Class A common stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Kynam Capital Management, LP","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":4.01,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0001907884-26-000015","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":"92337R101","securityClass":"Class A common stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Yue Tang","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":4.01,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0000093751-26-000554","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001831828","issuerName":"VERA THERAPEUTICS INC","ticker":"VERA","cusip":"92337R101","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":4148786,"percentOfClass":5.8,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0002012383-26-003123","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":"92337R101","securityClass":"Class A Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":5340522,"percentOfClass":7.4,"filedAt":"2026-07-30","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0000080255-26-000426","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001831828","issuerName":"VERA THERAPEUTICS INC","ticker":"VERA","cusip":"92337R101","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":4573684,"percentOfClass":6.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0000902664-26-001831","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":"92337R101","securityClass":"Class A Common Stock, par value $0.001 per share","eventDate":"2026-03-25","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":1229525,"percentOfClass":1.7,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0000902664-26-001831","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":"92337R101","securityClass":"Class A Common Stock, par value $0.001 per share","eventDate":"2026-03-25","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":1229525,"percentOfClass":1.7,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0000902664-26-001831","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":"92337R101","securityClass":"Class A Common Stock, par value $0.001 per share","eventDate":"2026-03-25","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1229525,"percentOfClass":1.7,"filedAt":"2026-04-01","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0000102909-26-002499","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001831828","issuerName":"Vera Therapeutics Inc","ticker":"VERA","cusip":"92337R101","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0001172661-26-001342","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":null,"securityClass":"Class A common stock, $0.001 par value per share","eventDate":"2026-03-04","reportingPerson":"Deep Track Biotechnology Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":3921362,"percentOfClass":5.5,"filedAt":"2026-03-11","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0001172661-26-001342","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":null,"securityClass":"Class A common stock, $0.001 par value per share","eventDate":"2026-03-04","reportingPerson":"Deep Track Capital, LP","reportingCik":null,"personType":"IA,OO","sharesOwned":3921362,"percentOfClass":5.5,"filedAt":"2026-03-11","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0001172661-26-001342","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":null,"securityClass":"Class A common stock, $0.001 par value per share","eventDate":"2026-03-04","reportingPerson":"David Kroin","reportingCik":null,"personType":"HC,IN","sharesOwned":3921362,"percentOfClass":5.5,"filedAt":"2026-03-11","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0001104659-26-023756","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":null,"securityClass":"Class A Common Stock, $0.001 par value","eventDate":"2025-12-10","reportingPerson":"Dr. Maha Katabi (\"Katabi\")","reportingCik":null,"personType":"IN","sharesOwned":2847837,"percentOfClass":4,"filedAt":"2026-03-05","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0001104659-26-023756","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":null,"securityClass":"Class A Common Stock, $0.001 par value","eventDate":"2025-12-10","reportingPerson":"Sofinnova Venture Partners X, L.P. (\"SVP X\")","reportingCik":"0001680200","personType":"PN","sharesOwned":2793987,"percentOfClass":3.9,"filedAt":"2026-03-05","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0001104659-26-023756","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":null,"securityClass":"Class A Common Stock, $0.001 par value","eventDate":"2025-12-10","reportingPerson":"Sofinnova Management X, L.P. (\"SM X LP\")","reportingCik":null,"personType":"PN","sharesOwned":2793987,"percentOfClass":3.9,"filedAt":"2026-03-05","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0001104659-26-023756","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":null,"securityClass":"Class A Common Stock, $0.001 par value","eventDate":"2025-12-10","reportingPerson":"Sofinnova Management X-A, L.L.C. (\"SM X LLC\")","reportingCik":null,"personType":"OO","sharesOwned":2793987,"percentOfClass":3.9,"filedAt":"2026-03-05","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0001104659-26-023756","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001831828","issuerName":"Vera Therapeutics, Inc.","ticker":"VERA","cusip":null,"securityClass":"Class A Common Stock, $0.001 par value","eventDate":"2025-12-10","reportingPerson":"Dr. James I. Healy (\"Healy\")","reportingCik":null,"personType":"IN","sharesOwned":2793987,"percentOfClass":3.9,"filedAt":"2026-03-05","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0000080255-26-000281","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001831828","issuerName":"VERA THERAPEUTICS INC","ticker":"VERA","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":5461988,"percentOfClass":7.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0000315066-26-000540","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001831828","issuerName":"VERA THERAPEUTICS INC","ticker":"VERA","cusip":null,"securityClass":"CLASS A COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":2885853,"percentOfClass":4.1,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0000315066-26-000540","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001831828","issuerName":"VERA THERAPEUTICS INC","ticker":"VERA","cusip":null,"securityClass":"CLASS A COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":2885853,"percentOfClass":4.1,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0000102909-26-000262","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001831828","issuerName":"Vera Therapeutics Inc","ticker":"VERA","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":3570401,"percentOfClass":5.03,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/vera"},{"accessionNo":"0000080255-25-000840","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001831828","issuerName":"VERA THERAPEUTICS INC","ticker":"VERA","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":3666598,"percentOfClass":5.7,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/vera"}],"updatedAt":"2026-11-04T05:20:32.751Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/vera","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}